· First, summarize the article attached titled: Prenatal Exposure to Progesterone Affects Sexual Orientation in Humans and describe the biological basis of sexual orientation, including the brain regions, neurotransmitters, and hormones that may be associated with sexual orientation. Also consider any developmental factors that may influence later sexual orientation. Include any relevant anatomical or physiological markers that seem to be associated with a particular sexual orientation.

· Summarize your article on the biological basis of sexual orientation in enough detail that your reader will understand what was done in the study and what the results of the study.

· Finally, develop and describe a high-level overview of an educational program about the biological basis of sexual orientation. This should be appropriate to present to a middle school biology class. What would you include in this educational program? What would you not include in the educational program? How would you convey the ideas you have described in this week’s Assignment in a way that would not offend your audience, but would also minimize the giggles of young teenagers?

*** The article attached must be used, please cite from the article attached and other sources!***

Running head: ACADEMIC CLINICAL SOAP NOTE 1

PAGE

2

ACADEMIC CLINICAL SOAP NOTE

Academic Clinical Soap Note

SUBJECTIVE

Chief Complaint:

Patient is in clinic today for second peptide receptor radionuclide treatment (PRRT) with Lutathera treatment.

Background:

This is a pleasant 47-year-old female with a history of metastatic pancreatic neuroendocrine tumor. She was initially diagnosed in October 2016 presenting with pneumonia with an incidental lung nodule noted. Biopsy demonstrated low-grade neuroendocrine of 1%. She then was noted to have metastatic disease in the right breast biopsy proven in February 2017. Somatostatin analog therapy was initiated then. When the patient progressed in September 2017 she was transitioned to Afinitor. A right thyroid nodule was noted and biopsied in December 2018 with benign findings. That due to Tait scan in January 2019 showed progression of disease. She was transitioned to Capoten for one cycle with recurrence of pancreatitis as well as development of splenic vein thrombus in February 2019. She had persistent pancreatitis in March 2019 on CT imaging. After, GI tumor board review at Stony Brook University Hospital she was found to be metastatic low-grade neuroendocrine tumor more likely pancreatic origin. Because of persistent abdominal pain she underwent celiac plexus block in May 2019. She was subsequently referred for peptide receptor radionuclide therapy/ Lutathera and received first dose on 7/17/2019. She has recently moved to Florida 3 weeks ago and presents to reestablish for continuation of Lutathera treatment at Moffitt Cancer Center.

Family History:

Father died of prostate cancer in 1998. Mother had diabetes, heart disease, and hypertension, she passed in 2010. Patient state she had several uncles that died from cancer, but she does not recall which cancer they had.

Medication:

· Insulin (Lantus) glargine 20 unit(s), SubQ, DAILY.

· fluticasone nasal (Flonase 50 mcg/inh nasal spray) 2 spray(s), NASAL, DAILY.

· pancrelipase 6000 units oral delayed release capsule, PO, QID.

· Simvastatin 10 mg, 1 tab(s), PO, Bedtime

· Metoprolol 50 mg, 1 tab(s), PO, Daily

· NIFEdipine 30 mg, 1 tab(s), PO, Daily

· Losartan (losartan 100 mg oral tablet) 100 mg, 1 tab(s), PO, AS NEEDED.

· Multivitamin (Multi Vitamin+) PO, DAILY

· Vitamin C lozenge 500 mg, 1 tab(s), PO, Daily

· Multivitamin with iron (Iron 100 Plus) PO, DAILY.

· Multivitamin (Vitamin B Complex oral capsule) 1 cap(s), PO, Daily

· Biotin (biotin 5000 mcg oral tablet, disintegrating) PO, DAILY

Review of Systems:

Constitutional: She has a long-term history of fatigue. Weight loss of 30lb since beginning of 2019. No fever, no chills, no weakness, no decrease activity.

Eye: No recent visual problem, No double vision.

Ear/Nose/Mouth/Throat: No dry mouth, No nasal congestion, No mouth sores, No mucositis.

Respiratory: No shortness of breath, No cough, No sputum production.

Cardiovascular: No palpitations, No bradycardia, No tachycardia.

Breast: No nipple discharge.

Gastrointestinal: Occasionally nausea with no vomiting. She has constipation alternating with diarrhea. Stomach pain 4 on scale 0-10. Last bowel movement today.

Genitourinary: No dysuria, No hematuria.

Gynecologic: Negative.

Hematological/Lymphatics: No bruising tendency, No bleeding tendency.

Endocrine: No cold intolerance, No heat intolerance.

Immunologic: No recurrent fevers, No recurrent infections.

Musculoskeletal: No claudication.

Integumentary: No rash.

Neurologic: Alert and oriented X4.

Psychiatric: Not delusional, No hallucinations.

OBJECTIVE

Vital Signs:

Temperature: 98.65 Heart Rate: 74, Blood Pressure: 112/74, Respiratory Rate: 14, SpO2: 100%, Weight: 57.3kg, Height: 5 ft 6 in and BMI: 21.1

Physical Examination:

General: Compared weight chart and noted a 30lb weight loss. Alert and oriented, No acute distress.

HEENT: Oropharynx clear, Normocephalic, Oral mucosa is moist.

Cardiovascular: Normal rate, Good pulses equal in all extremities.

Respiratory: Lungs are clear to auscultation, Symmetrical chest wall expansion.

Gastrointestinal: Pain elected on lite palpation soft. Non-tender, Non-distended. Hematological/Lymphatics: Lymphatic exam: Right, Submandibular, 10 mm ( By 10 mm ). Extremities: Normal range of motion, No deformity, Normal gait.

Integumentary: Warm, Intact.

Neurologic: Normal sensory, No focal defects.

Cognition and Speech: Speech clear and coherent, Functional cognition intact.

Psychiatric: Cooperative, Appropriate mood & affect

Labs/Imaging/ Diagnostic Test Result:

Abnormal Labs: Glucose- 219 H: Mean Cell Volume: 94.2 H: RDW: 52.7 H:

Diagnostic Data: Detailed review of the PET/CT: demonstrates numerous metastatic avid lesions within the soft tissues and osseous structures involving bilateral breasts, liver, pancreas, metastatic lesion in the left peritoneum and irregular mass in the left pelvis and persistent multiple osseous metastasis.

ASSESSMENT/CLINICAL IMPRESSIONS

Health Problems:

1. Neuroendocrine Tumor D3A.8

2. Pancreatitis K85

3. Diabetes E23.2

4. Hyperlipidemia E78.49

Differential Diagnosis:

ICD-10 K29: Zollinger-Ellison Syndrome- is characterized by gastric acid hypersecretion resulting in severe acid-related peptic disease and diarrhea. The tumors are thought to emerge from the delta cells that are found in the pancreas and it was founded to account for about 25% to 40% of gastrinomas. The rest of the endocrine tumors to include the 50- 70% of abnormal cells were found in the small digestive tract, while about 5% emerge from other intra-stomach area. “Gastric not only directly stimulates parietal cell secretion but also causes expansion of the mass of parietal cells. The increase in parietal cells results in an increase in basal acid output and maximal acid output. This substantial secretion of acid results in gastroesophageal reflux disease (GERD) symptoms and damage to the mucosal lining of the GI tract, causing peptic ulcers. In addition, the acid inactivates pancreatic enzymes, which contributes to the diarrhea, steatorrhea, and malabsorption of lipid-soluble nutrients (www.epocrate.com.2019).”

ICD-10 E34.0: Carcinoid Syndrome- progress in some people with carcinoid tumors and is identified by cutaneous flushing, abdominal cramps, and diarrhea. There are a number of symptoms relevant to CS that healthcare work looks for such as the abnormal labs are the first to investigate then there are the physical manifestations. Carcinoid syndrome is seen in individuals who have an underlying carcinoid tumor that has spread to the liver. Carcinoid syndrome is a rare condition that effect about 10% of the population. “Carcinoid syndrome may be more prevalent than suspected because diagnosis is difficult and sometimes overlooked; some patients may not exhibit all three of the hallmark symptoms of flushing, wheezing, and diarrhea (www.raredisease.org. 2019).”

ICD-10 D35.00: Pheochromocytoma- Is the type of “tumor arising from catecholamine-producing chromaffin cells of the adrenal medulla that classically presents with headaches, diaphoresis, and palpitations in the setting of paroxysmal hypertension (www.epocrate.com 2019).” This disease secrete adrenaline in an uncontrolled manner and can cause severe medical issues including heart disease, stroke, and ultimate this can lead to death.

PLAN COMPONENT MANAGEMENT:

Research has shown that there are few neuroendocrine tumors that may not have a clear primary tumor site and these tumors will be treated based on the histology. Many neuroendocrine tumors tend to poorly differentiated and may grow and spread rapidly. In order to get a better understanding of the tumor dynamic imaging studies a long with scopes to see the internal area of the tumor body will be utilized by the provider. EUS and biopsy may be done to confirm the cell type. The initially diagnostic test can start with the CT of the chest, abdomen, and/ or pelvis, MRI, FDG_PET/ CT scan, and biochemical testing. The patient that has a poorly differential neuroendocrine tumor the treatment option ideally utilizes a combination of options. The doctor will decide which treatment will work best, for the patient at that time; “one treatment option is the surgical option this will include resection + adjuvant chemotherapy +/- radiation therapy. There is locoregional surgical option that involves radiation therapy and chemotherapy given at the same time or one treatment after the other or just chemotherapy only. If the neuroendocrine tumor is metastatic than the treatment option is chemotherapy and every three months the patient will come into the clinic and have his/ her lab drawn and CT or MRI completed to check the progression of the treatment and at the time the provider and patient will decide based on the diagnostic report how to proceed (www.nccn.org. 2019).”

Providers at the Moffitt cancer center have used peptide receptor radionuclide therapy (PRRT) with great success. “The FDA approval of Lutathera, a peptide receptor radionuclide therapy (PRRT), on January 26, 2018, for a new era in treatment options for the neuroendocrine tumor (www.newRx.org. 2016).” When PRRT is use it was found to manifest long term effectiveness to the treatment of neuroendocrine tumor while also allowing the patient to maintain a high-quality lifestyle. The patient can use PRRT repeatedly with very little side effects and rarely these patients were dialysis dependent.

“All PRRT candidates must first be seen by an Oncologist in order to be evaluated for treatment. The requests for PRRT treatment should be for a GI oncology consult (De Visser, M., 2008).” Cost associated with the PRRT can be costly but patient who do not have insurance, Medicare/ Medicaid there are programs that can help with getting qualified for therapy. The PRRT drug can be offered free to the patient that do not have insurance but there will be costs for medications to help with the side effect of PRRT such as nausea and vomiting, and there will be costs to the institution and medical personnel providing the service.

Disposition/ Discharge Plan:

Peptide Receptor Radionuclide Therapy uses radiation to kill cancer cells, this mean that this medication works differently than other cancer drugs. PRRT is given in a hospital setting and have two components to the therapy (Thang. S. P., et.al 2018).” There is the tumor targeted part that finds the cancer cell with a receptor called somatostatin. Then there is the radioactive component that actually kills the cancer cell. This cancer infusion is given up to four times and eight weeks apart from each infusion. Once the infusion has completed the patient will be given an injection of long acting octreotide to decrease the cancer from growing or spreading. The patient will be given anti-nausea medication, amino acid hydration solution medication, and then 45 minutes later the patient will receive the PRRT treatment.

The nurse will explain during the discharge planning that it is imperative that the patient must drink a lot of fluids/ water and urinate frequently before, during and after treatment because this will help the radiation to leave the body. Patient should also limit close contact with pregnant women, children, and immune compromised patient for the first two weeks after therapy to prevent exposure and the patient must practice good hand hygiene with soap and water often. Expected outcome of PRRT is to “reduce the risk of cancer spreading, growing, or getting worse by 79% compared to a larger than normal dose of long-acting octreotide (www.carcinoid.org. 2019).”

Health Education/ Promotion and Disease Prevention:

Patient education/ health promotion include “minimize radiation exposure during and after treatment with PRRT-consistent with institutional good radiation safety practices and patient management procedures, monitor blood cell counts because of myelosuppression; treatment may be placed on hold, dose educed, or permanently discontinue PRRT treatment based on negative reaction to treatment, hepatotoxicity can cause a decrease in blood levers therefore monitor transaminases, bilirubin and albumin. Due to neuroendocrine hormonal crisis patient must be monitored for flushing, diarrhea, hypotension, bronchoconstriction or other signs and symptoms, embryo-fetal toxicity can occur with PRRT in which the fetal harm can come about. Advise females and males of reproductive potential of the potential risk to a fetus and to use effective contraception and PRRT can cause infertility (www.carcinoid.org. 2019).” Patient are also instructed to make sure they continue to update their medication list to prevent adverse reaction. Disease prevention focus is on consuming half the patient body weight in water daily, eating a healthy diet that consist of fresh fruit and vegetable, avoid white pasta and rice, organic meats, fruits, and vegetables is considered a better choice (think rainbow colors when it comes to healthy eating). Maintaining a healthy weight and BMI. Patient are instructed to work out 150 minutes per week about 3 to 4 times in that week, stress reduction is another prevention option, and finally getting enough rest so that the body can fight off the cancer cell that is circulating in the body.

References

Carcinoid Syndrome. (2019). Retrieved from https://rarediseases.org/rare-diseases/carcinoid-syndrome/

de Visser, M., Verwijnen, S. M., & de Jong, M. (2008). Update: Improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biotherapy & Radiopharmaceuticals, 23(2), 137-57. doi:http://dx.doi.org.lopes.idm.oclc.org/10.1089/cbr.2007.0435

Neuroendocrine cancer; long-term experience supports efficacy and safety of PRRT for treating neuroendocrine tumors. (2016, Nov 06). NewsRx Health Retrieved from https://lopes.idm.oclc.org/login?url=https://search-proquest-com.lopes.idm.oclc.org/docview/1832797816?accountid=7374

Pheochromocytoma. (2019). Retrieved from https://online.epocrates.com/diseases/16332/Pheochromocytoma/Risk-Factors

Thang, S. P., Mei, S. L., Kong, G., Hofman, M. S., Callahan, J., Michael, M., & Hicks, R. J. (2018). Peptide receptor radionuclide therapy (PRRT) in european neuroendocrine tumour society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. European Journal of Nuclear Medicine and Molecular Imaging, 45(2), 262-277. doi:http://dx.doi.org.lopes.idm.oclc.org/10.1007/s00259-017-3821-2

Treatment Guideline: Neuroendocrine Tumors. (2019). Retrieved from https://www.nccn.org/patients/guidelines/neuroendocrine/88/

What is LUTATHERA®? (2019). Retrieved from https://www.carcinoid.org/wp-content/uploads/2018/07/AAA_Lu177_US_0058_LUTATHERA_lutetitum_Lu177_dotatate_Patient_Fact-Sheet_Final-July-2018.pdf

Zollinger-Ellison syndrome. (2019). Retrieved from https://online.epocrates.com/diseases/40824/Zollinger-Ellison-syndrome/Etiology27, 2018, from https://www.atsjournals.org/doi/citedby/10.1513/pats.200604-099SS

image1.png

Rubic_Print_Format

Course Code Class Code Assignment Title Total Points
ANP-650 ANP-650-XO0103XB Academic Clinical SOAP Note 65.0
Criteria Percentage Excellent (100.00%)
Content 70.0%
Primary or Working Diagnosis 10.0% A one-sentence description of the primary working diagnosis, pending differential diagnoses, and context or service in which the patient is being seen is provided and includes supporting details.
Brief Clinical Course 10.0% A one-to-two paragraph description of the current illness or hospital stay, including pertinent diagnostic findings or procedures and the number of days since the patient has been hospitalized, is complete with supporting documentation.
Review Of Systems 10.0% Five systems affected by the working diagnosis, along with two positive or negative effects of the diagnosis on each system, are provided with thorough details and support.
Exam 10.0% Five systems examined within the last 24 hours, including two positive or negative findings relevant to each system and a full set of vital signs, are provided with thorough details and support.
Diagnostics 10.0% Admission diagnostics are provided with thorough details and support.
Impression or Assessment 10.0% Identification of all acute and chronic diagnoses in order of ICD-10 priority and any differential diagnoses being eliminated are provided with thorough details and support.
Plan 5.0% A treatment plan that corresponds with the diagnosis and includes admission type, diagnostics, medications and dosages, and any consults or follow-up procedures needed is provided with thorough details and support.
Geriatric Specific Care 5.0% A discussion of ethical, legal, or geriatric considerations is provided with thorough details and support.
Organization and Effectiveness 10.0%
Mechanics of Writing (includes spelling, punctuation, grammar, language use) 10.0% Writer is clearly in command of standard, written, academic English.
Format 20.0%
Paper Format (Use of appropriate style for the major and assignment) 10.0% All format elements are correct.
Documentation of Sources (citations, footnotes, references, bibliography, etc., as appropriate to assignment and style) 10.0% Sources are completely and correctly documented, as appropriate to assignment and style, and format is free of error.
Total Weightage 100%

Academic Clinical SOAP Note

Academic clinical SOAP notes provide a unique opportunity to practice and demonstrate advanced practice documentation skills, to develop and demonstrate critical thinking and clinical reasoning skills, and to practice identifying acute and chronic problems and formulating evidence-based plans of care.

Develop a hospital follow-up progress SOAP note based on a clinical patient from your practicum setting. In your assessment, provide the following:

· A one-sentence description of the primary working diagnosis, pending differential diagnoses, and the context or service in which the patient is being seen.( Acute Care Hospital)

· A one-to-two paragraph description of the current illness or hospital stay, including pertinent diagnostic findings or procedures. Include how many days the patient has been hospitalized, if applicable.

· List of at least five systems affected by the working diagnosis. Provide two positive or negative effects that the working diagnosis has on each system.

· List of at least five systems examined within the last 24 hours. Provide at least two pertinent positive or negative findings relevant to each system examined and include a full set of vital signs.

· List of all admission diagnostics conducted for this visit or conducted within the last 24 hours.( (CPT codes)

· List of all pertinent acute and chronic diagnoses in order of priority using ICD-10. Identify any differential diagnoses being eliminated.

· Treatment plan that corresponds with the diagnosis. Provide information on admission type, types of diagnostics, any prescribed medications and dosages, and any relevant consults or follow-up procedures needed.

· Discussion of any relevant ethical, legal, or geriatric-specific considerations.

Incorporate at least 3-5 peer-reviewed articles in the assessment or plan. (Minimum 1200 words).

Don’t Forget to include all coding including ICD-10, CPT and all others.

While APA style is not required for the body of this assignment, solid academic writing is expected, and documentation of sources should be presented using APA formatting guidelines, which can be found in the APA Style Guide, located in the Student Success Center.

This assignment uses a rubric. Please review the rubric prior to beginning the assignment to become familiar with the expectations for successful completion.

You are required to submit this assignment to LopesWrite. Refer to the LopesWrite Technical Support articles for assistance.

ORIGINAL PAPER

Prenatal Exposure to Progesterone Affects Sexual Orientation in Humans

JuneM. Reinisch1,2,3 • Erik Lykke Mortensen3,4 • Stephanie A. Sanders1,5

Received: 18 June 2013 / Revised: 15 December 2016 /Accepted: 15 December 2016 / Published online: 3 April 2017

� Springer Science+Business Media New York 2017

Abstract Prenatal sexhormone levelsaffectphysicalandbehav-

ioralsexualdifferentiationinanimalsandhumans.Althoughprena-

tal hormones are theorized to influence sexual orientation in

humans, evidence is sparse. Sexual orientationvariables for 34

prenatally progesterone-exposed subjects (17 males and 17

females) were compared to matched controls (M age= 23.2

years). A case–control double-blind design was used drawing

on existing data from the US/Denmark Prenatal Development

Project. Index cases were exposed to lutocyclin (bioidentical

progesterone=C21H30O2;MW:314.46)andnootherhormonal

preparation. Controls were matched on 14 physical, medical,

and socioeconomic variables. A structured interview conduc-

ted by a psychologist and self-administered questionnaires

were used to collect data on sexual orientation, self-identifi-

cation,attractiontothesameandothersex,andhistoryofsexual

behavior with each sex. Compared to the unexposed, fewer

exposedmalesandfemales identifiedasheterosexualandmore

of them reported histories of same-sex sexual behavior, attrac-

tiontothesameorbothsexes,andscoredhigheronattractionto

males.Measuresofheterosexualbehaviorandscoresonattrac-

tiontofemalesdidnotdiffersignificantlybyexposure.Wecon-

clude that, regardless of sex, exposure appeared to be associ-

atedwithhigherratesofbisexuality.Prenatalprogesteronemaybe

an underappreciated epigenetic factor in human sexual and psy-

chosexual development and, in light of the current prevalence of

progesterone treatment during pregnancy for a variety of preg-

nancy complications, warrants further investigation. These data

ontheeffectsofprenatalexposuretoexogenousprogesteronealso

suggest a potential role for natural early perturbations in proges-

terone levels in the development of sexual orientation.

Keywords Sexual orientation � Prenatal progesterone exposure � Bisexuality � Sexual behavior

Introduction

Although prenatal gonadal hormones have been theorized to

influence sexual orientation in humans, other than recent

research using a surrogate measure (2D:4D digit ratio) for pre-

natalandrogenexposure(Hiraichi,Sasaki,Shikishima,&Ando,

2012; Wong & Hines, 2015), evidence from studies of exoge-

noushormoneexposure is sparse (Adkins-Regan, 1988;Ellis&

Ames, 1987; Gooren, 2006; Hines, 2011; Hines, Constanti-

nescu, & Spencer, 2015; Meyer-Bahlburg, 1984). Despite rel-

atively frequent current administration of exogenous proges-

terone to pregnant womenwith a variety of clinical problems,

even less attention has been paid to the possible role of prenatal

exposure to progesterone on any aspect of human sexual and

psychosexual development (Kester, Green, Finch,&Williams,

1980; Reinisch, Ziemba-Davis, & Sanders, 1991; Sanders &

Reinisch, 1985; Wagner, 2008). Perhaps this is due to the ele-

vated levels of natural progesterone present during gestation lead-

ing to the assumption that additional exogenous doses would not

affect these aspects of development.

& June M. Reinisch [email protected]

1 The Kinsey Institute for Research in Sex, Gender and

Reproduction, Indiana University, Morrison Hall 313,

Bloomington, IN 47405, USA

2 The Museum of Sex, New York, NY, USA

3 Institute of Preventive Medicine, Copenhagen University

Hospital, Copenhagen, Denmark

4 Department of Public Health, University of Copenhagen,

Copenhagen, Denmark

5 Department of Gender Studies, Indiana University,

Bloomington, IN, USA

123

Arch Sex Behav (2017) 46:1239–1249

DOI 10.1007/s10508-016-0923-z

The prenatal hormone or neuroandrogenic theory of sexual

orientation (Ellis & Ames, 1987; Gooren, 2006; Hines, 2010;

Meyer-Bahlburg, 1984) assumes that heterosexuality is an in-

herent part of ‘‘normal’’ sexual differentiation and that homo-

sexuality (as evidenced by self-identification, same-sex sexual

behavior, or attraction/desire) is a result of perturbations in the

typical prenatal hormone environment. Specifically, the theory

suggests that homosexuality is the result of insufficient prenatal

androgenexposureoraction inmalesandexcessprenatalandro-

gen exposure in females during sensitive periods of early devel-

opment.Thus,homosexuality isviewedassomedegreeof femi-

nization and/or demasculinization of males and of masculin-

izationand/ordefeminizationof females.Bisexuality inhumans

isoften thoughtofas‘‘partialhomosexuality’’orasmovingaway

from‘‘exclusive heterosexuality’’toward amiddle point along a

bipolar unidimensional continuum between exclusive hetero-

sexuality and exclusive homosexuality (Kinsey, Pomeroy, &

Martin, 1948).ThisbipolarKinseyscalemodel implies a trade--

off betweenheterosexuality andhomosexuality—themorehomo-

sexual, the lessheterosexual (seeSanders,Reinisch,&McWhirter,

1990).

For ethical reasons, support for the formative role of prenatal

sex hormones in the development of sexual orientation is based

primarily on experiments with animals (Adkins-Regan, 1988;

Balthazart, 2011; Hines, 2011; Meyer-Bahlburg, 1984), a few

clinical studies of humans whose prenatal hormone environ-

ments were altered bymetabolic anomalies (Cohen-Bendahan,

van de Beek, & Berenbaum, 2005; Hines, 2004, 2010, 2011;

Jordan-Young,2012;Meyer-Bahlburg, 1984), ormaternalmedi-

cal treatment with estrogenic compounds during gestation

(Meyer-Bahlburgetal.,1995),andmostrecentlythestudiesusing

digit ratio measures to reflect the prenatal gonadal hormone

environment (Grimbos,Dawood,Burris,Zucker,&Puts,2010;

Wong&Hines, 2015). Critiques (Adkins-Regan, 1988; Balt-

hazart,2011;Hines,2011;Meyer-Bahlburg,1984;Valla&Ceci,

2011) of this perspective and its putative supportive animal

research include: (1) conflation of heterotypic sexual behavior in

animals (i.e., acceptingmounts inmalesormountingby females)

andhumanhomosexuality (e.g., themale ratwhomounts another

maleisnotconsidered‘‘homosexual,’’whilethemountedmaleis);

(2) limitations in extrapolating from phylogenetically distant ani-

mals to humans; and (3) the focus on copulatory (consummatory)

behaviorsinanimalmodelsratherthanmatepreference(appetitive)

behaviors.Additionally, studies inhumansaregenerally limitedor

complicatedbysmallsamplesize; inadequateor inappropriate

matches or‘‘control’’groups; insufficient assessment of sexual ori-

entationorhormoneexposure;mixedhormonalexposures; exoge-

nous exposure to synthetic rather than naturally occurring hor-

mones;alterationsofgenitalanatomyrelatedtohormoneexposure;

confoundswithothermetabolic andphysical correlates of intersex

conditions; and/or simultaneousexposures toother treatmentcom-

pounds.Nonetheless, there is substantial evidence that early expo-

suretosexhormonesinfluencesanatomical,physiological,and

sexually dimorphic behavioral development in animals and

humans(Cohen-Bendahanetal.,2005;Reinisch,1974;Reinisch&

Sanders, 1984, 1987; Reinisch et al., 1991). Thus, investigation of

theroleofprenatalsexhormonesinthedevelopmentofhumansex-

ual orientation incorporatingmore effective controls is warranted.

Ithasbeensuggestedthat thepotential roleofprogesterone in

mammalian sexual differentiation and development has been

insufficiently investigated (Dodd, Jones, Flenady, Cincotta, &

Crowther, 2013; Wagner, 2008). Although androgenic, estro-

genic, and antiandrogenic compounds have received attention

(includingsyntheticprogestins, someofwhichhaveandrogenic

effects), therehasbeenrelatively littleexaminationof the roleof

progesterone, despite its demonstrated antiandrogenic and antie-

strogenic effects on some systems (Dorfman, 1967; Sanders &

Reinisch,1985).Progesteroneandsyntheticprogestinsarecom-

monly prescribed during early pregnancy for luteal phase sup-

port during in vitro fertilization and for threatened abortion

(Aboulghar,2009;Bakeret al., 2014,Palagianoetal., 2004)and

later in pregnancy for prevention of premature birth and low

birth weight (da Fonseca, Bittar, Damião, & Zugaib, 2009).

Few studies have examined the long-term physical and

behavioral outcomes of either naturally occurring or synthetic

progestin exposure in humans (Cohen-Bendahan et al., 2005;

Hartwig et al., 2014; Hines, 2004, 2010; Northen et al., 2007;

Reinisch,1974,Reinisch&Sanders,1984,1987;Reinischetal.,

1991). Maternal intake of synthetic progestins and/or proges-

terone during pregnancy has been found to be associated with

increased hypospadias (urinary opening on the underside of the

penis instead of the tip) risk in males (Carmichael et al., 2005;

Dorfman, 1967; Silver, Rodriguez, Chang, & Gearhart, 1999)

and alteration of some sex-differentiated behavior patterns in

male and female offspring (Cohen-Bendahan et al., 2005; Ehr-

hardt, Grisanti, & Meyer-Bahlburg, 1977; Kester et al., 1980;

Reinisch, 1974, 1977, 1981;Reinisch&Karow,1977;Reinisch

& Sanders, 1984, 1987; Reinisch et al., 1991; Sanders & Rein-

isch, 1985).

One of these studies examined the effects of ‘‘natural’’ pro-

gesterone on sex/gender development (Kester et al., 1980). It

included 10 men (19–24years) exposed prenatally to natural

progesteronealoneandacontrolgroupmatchedondateofbirth,

age of mother, and, in most cases, prior numbers of siblings.

Progesterone-exposed subjects‘‘tended to recall boyhood behav-

iors which departed from the conventional male mode toward

‘femininity’’’and those subjects exposed to higher doses scored

loweron theBemSex-Role InventoryMasculine scale and lower

on the Feminine scale. A more recent study of fetal exposure to

prescriptiondrugsand sexualorientationdidnotfindasignificant

relationship between maternal reports of progesterone/progestin

exposure and sexual orientation, but the study was limited by its

1240 Arch Sex Behav (2017) 46:1239–1249

123

reliance on maternal recall of medical treatment often decades

earlier, among other methodological issues (Ellis & Hellberg,

2005).

Inlightofthesefindingsandthedearthofdataontheoffspring

of progesterone-treated pregnancies,we compared data on sex-

ual orientation and attraction from young adults who were

exposed in utero to progesterone (bioidentical progesterone=

C21H30O2;MW: 314.46) viamaternalmedical treatment to data

fromunexposedmatched controls.The study employeda case–

control, double-blind, prospective, longitudinal design using

membersofabirthcohortwithmatchingofcasesandcontrolson

14 physical, medical, and socioeconomic variables that were

recorded prenatally or at birth; careful evaluation of prenatal

hormone exposure; and assessment of sexual orientation and

attraction. Based upon the limited animalmodels and human

research, we hypothesized that progesterone-exposed human

offspring would show more same-sex attraction and behavior

with more exposed subjects identifying as non-heterosexual.

Method

Participants

Data from 34 subjects (17men and 17women) prenatally ex-

posed exclusively to lutocyclin and no other hormonal prepa-

ration, and their individuallymatched unexposed controlswere

drawn from an existing database, the US/Denmark Prenatal

Development Project (PDP) (Reinisch, Mortensen, & Sanders,

1993). Lutocyclin is identified as progesterone (bioidentical pro-

gesterone=C21H30O2; MW: 314.46) in the Danish Physician’s

Desk Reference (Junager & Schleisner, 1963) and was admin-

isteredduringpregnancy to treat cases of potentialmiscarriage as

indicated by staining or bleeding, abortion imminens (threatened

abortion), or maternal history of repeatedmiscarriage.Mean age

of the participants at the time of assessment for this study was

23.2years (SD=1.4).

Participants were drawn from the Copenhagen Perinatal

Cohort, comprising all 9125 offspring born at the University

Hospital in Copenhagen, Denmark, between 1959 and 1961.

During the establishment of the cohort, demographic, socioe-

conomic, and medical variables were prospectively recorded

pre-, peri-, and postnatally. Potential participants for the current

study were identified through the available computerized data-

base. Exclusion criteria were: offspring of incest; gestation

length less than 28weeks; congenital malformation (including

genital ambiguity); Down’s syndrome;maternal history of dia-

betes,epilepsyorCNSdisorder;maternaltreatmentwiththyroid

medication;maternalpsychosisorsyphilis;mother less thanage

16 at time of delivery; and mother diagnosed with polio,

encephalitis, meningitis, viral pneumonia, or ornithosis during

pregnancy. The original datatape only coded yes/no for drug

exposure in terms of the class of drug administered (hormone,

barbiturate, antiepileptic, etc.) for at least 5 days during each of

six gestational periods, coded into trimesters for these analyses.

Original hospital records for all hormone-exposed cases and

their matched controls were reviewed by our team to confirm

exclusion criteria and to obtain specific information on dosage,

timing, and duration of exposure to all gestational treatments.

All eligible cases were recruited to participate in the PDP. The

overallparticipationrateforthePDPwas87%.Extensivedetails

of the methodology are reported elsewhere (Reinisch et al.,

1993; Reinisch, Sanders, Mortensen, & Rubin, 1995). Partici-

pants only knew theywere recruited due to their inclusion in the

Danish Perinatal Cohort at birth butwere blind as to their expo-

sure status.

Of the45casesexposedto lutocyclininthePDPdatabase, the

34 included here were those exposed to lutocyclin and no other

hormonal preparation, so that anyobservedeffects of lutocyclin

would not be confounded by exposures to other hormones.

Matches were chosen from 271 non-exposed controls selected

from a large pool of similarly evaluated PDPmembers.

Matching occurred in two stages using 14 variables with

exact matching for sex. The objective of the matching was to

obtain a set of control subjectswhose distributions onmatching

variableswereascloseaspossibletothedistributionsofexposed

subjects. First, usingMahalanobismetricmatchingwithin cali-

pers defined by the estimatedpropensity score for each exposed

case, the 10 statistically best potential controls were identified

(Rosenbaum & Rubin, 1985a, 1985b) and then the Project

Director (J.M.R.)matched one or two potential controls to each

exposed case for inclusion in the study. Details of thematching

procedure have been published elsewhere (Reinisch et al.,

1993, 1995). Table 1 shows that therewere no significant group

differences (exposedvs. unexposed) in the distributions ofmat-

ching variables.

WhenthePerinatalCohortwasestablished,pregnantwomen

were interviewedas soonas theywere enrolled for prenatal care

about whether they were married or single, had planned the

pregnancy at the time of conception, or had attempted abortion

(Villumsen, 1970). For exposed cases, there was one single

mother (2.9%), one unplanned pregnancy (2.9%, not the same

person), and no abortion attempts. For the matched control

sample,23%ofthemothersweresingle,44%of thepregnancies

were unplanned, and 12% had attempted abortion. The per-

centagesfortheoverallcohortwere37,56,and7%,respectively.

It is not surprising that special treatment for pregnancy main-

tenancewas confoundedwith beingmarried, planning orwant-

ingthepregnancy,andnotattemptingabortion.Therefore, these

were not used asmatching variables.At the time, relatively few

coupleswere living togetherwithout beingmarried and being a

single mother may have presented difficulties. We do not

interpret thesepotentialconfoundsaspotentialcausativefactors

for same-sex (homosexual/bisexual) behavior and attraction. In

thePDPsampleofmorethan550participants, thesethreemater-

Arch Sex Behav (2017) 46:1239–1249 1241

123

nal variables were unrelated to offspring sexual orientation, at-

traction, or sexual behavior in either sex.

Lutocyclin exposure parameters in the present sample were

asfollows:Meantotaldosagewas915mg(SD=1073.54,range

40–5400mg)with amean treatment duration of 61days (SD=

42, range 8–158). Average daily dose was calculated for each

individualbydividingtotaldosagebydurationof treatment.The

group mean of‘‘average daily dose’’was 18.41mg/day. Forty-

onepercent(n=14)wereexposedduringthefirsttrimesteronly,

35%(n=12)during thefirstandsecondtrimesters,17%(n=6)

during the second trimester only, and 6% (n=2) during the

second and third trimesters. Table2 shows detailed informa-

tion on dosage and timing of exposure. Nominimum exposure

parameters were set for selection; thus, these represent the nor-

mal rangeofdosagesanddurationscommonlyusedin treatment

of at-risk pregnancy in Denmark during this period. Exposures

did not differ by sex. Timing of exposure occurred during peri-

odsassociatedwithsexualdifferentiationof theCNSinhumans.

Measures

Interview Data

Information on sexual orientation was obtained as part of a

structured interviewconductedbyapsychologist at the Institute

for Preventive Medicine in Copenhagen, Denmark. Psycholo-

gists were blind to the exposure status of all subjects. The fol-

lowing sexual orientation variables were addressed in the

comprehensive interview and coded as follows.

Same-Sex Variables

1. Self-labeled sexual orientation: (heterosexual/non-hetero-

sexual) [This item was drawn from a question asking par-

ticipants whether they considered themselves to be hetero-

sexual,homosexual,bisexual,‘‘don’tknow.’’Giventhesmall

numbers in the non-heterosexual categories, the data were

recoded to heterosexual/non-heterosexual for analysis.]

Table 1 Distributions of matching variables for prenatally progesterone-exposed and unexposed participants

Matching variable Exposed

n= 34

Unexposed

n= 34

Statistica p

%Maleb 50.0 50.0 na

% Firstborn 61.8 50.0 z= .85 ns

Mean (SD) gestation length (week) 37.76 (3.10) 38.12 (1.80) t(32)\1 ns Mean (SD) birth weight (g) 31.13 (8.85) 30.99 (5.06) t(33)\1 ns Mean (SD) birth length (cm) 50.97 (4.66) 50.69 (2.29) t(33)\1 ns Mean (SD) socioeconomic statusc 6.00 (1.55) 5.94 (1.52) t(31)\1 ns Mean (SD) breadwinner’s educationd 3.07 (.78) 3.06 (.74) t(29)\1 ns Mean (SD) mother’s age (year) 30.03 (4.46) 31.15 (5.76) t(33)=-1.06 ns

Mean (SD) father’s age (year) 35.00 (6.03) 33.48 (7.12) t(32)= 1.04 ns

Mean (SD) PBC 415e 33.85 (17.91) 33.53 (16.12) t(33)\1 ns Mean (SD) maternal complaint scoref 2.96 (2.48) 3.22 (2.52) t(33)\1 ns % Severe preeclampsia 3.0 2.9 z= 0 ns

%Maternal respiratory illness 2.9 2.9 z= 0 ns

Mean (SD) maternal weight gain (kg)/height cubed (m)Wgt/hght 25.52 (9.05) 25.29 (7.35) t(23)\1 ns Mean (SD) no. of cigarettes/day in third trimester 4.42 (7.01) 5.74 (7.64) t(32)\1 ns

a na=Not applicable. Unless otherwise noted df= 33 b Exact match required for sex c Family socioeconomicstatuswhen thechildwas1 yearofage.Danishsystemcategorizedonaneight-point scale, 1= lowest, 8= highest.Pairswere

exactly matched on SES, except for two exposed cases with missing data who were matched to controls with SES= 4 d Education was categorized on a four-point scale, 1= remedial instruction, 4= college e Thepredisposing riskscore is avariable in theoriginal cohortdatatape. It is ascorebasedonpregravidas factors concernedwith themother’sphysical

and emotional state prior to the pregnancy. Information includes such items aswhether themother wasmarriedwhen she conceived, whether she had

previously had an abortion, a miscarriage, a stillbirth, or neonatal death; her age; her weight; and previous history of central nervous system illness,

syphilis, cardiovascular illness, or diabetes. The score indicates that conditions (physical and emotional) were probably ‘‘less than optimum’’ for

conception at the time. For the cohort, the scores range from 0 to 130 and the mean is 29.52 f Thematernal complaint score included the following: severepreeclampsia, hypertension, prescriptionofdiuretics, edemaandproteinuria, bleeding/

staining, allergies and treatment with antihistamines, and anemia

1242 Arch Sex Behav (2017) 46:1239–1249

123

2. Lifetime attraction to own sex: (yes/no)

3. Current attraction to own or both sexes: (yes/no)

4. Kissed own sex: (yes/no)

5. Having been partially undressed in a sexual situationwith

own sex: (yes/no)

6. Havingbeen fullyundressed inasexual situationwithown

sex: (yes/no)

7. ‘‘Intercourse’’with own sex: (yes/no) [Our interview data

indicated that women generally interpreted this question

to mean mutual genital sexual stimulation; men usually

interpreted this as anal intercourse.]

Other-Sex Variables

8. Having kissed other (‘‘opposite’’) sex: (yes/no and age at

first engagement)

9. Having been partially undressed in a sexual situationwith

other sex: (yes/no and age at first engagement)

10. Having been fully undressed in a sexual situation with

other sex: (yes/no and age at first engagement)

11. Intercoursewith other sex: (yes/no, and age at first engage-

ment).

Items 4–11 were coded from questions asking age at first par-

ticipation in each behavior, an approach developed by Kin-

sey (Kinsey et al., 1948;Kinsey, Pomeroy,Martin,&Gebhard,

1953). Asking age at first engagement signals participants that

one is non-judgmental about their engagement in particular

sexualbehaviors.Apostpubertal criterionwasapplied forageat

first engagement in thesebehaviors. Specifically, age at puberty

(whichwasassessedbyaseparatesetofquestionsaboutmarkers

ofpuberty)wascomparedtothereportedageatfirstengagement

in the behaviors. The very few reports of behaviors prior to

puberty were not included in these analyses as they could have

been childhood sexual exploration. This criterion was consis-

tently applied across all subjects and for both same-sex and

other-sex behaviors. The number of participants engaged in the

same-sexbehaviorswasinsufficient toconductastatisticalanal-

ysisofagefor thosevariables.However,wewereable toanalyze

age at first engagement in the heterosexual behaviors.

Questionnaire Data

Sexual Behavior Inventory (SBI) This self-administered

questionnaire was created for the PDP (Reinisch et al., 1993)

to assess whether or not 67 different sexual behaviors have

been tried. Three items on the questionnaire were relevant to

sexual orientation: (1) to ‘‘go to bed with’’ a person of your

own sex (in Danish, this item is understood to mean inter-

course or mutual genital contact); (2) to masturbate in the

presence of another person(s) of the same sex; and (3) to

masturbate in the presence of another person(s) of the oppo-

site sex.

SexualAttitudesQuestionnaire (SAQ) This self-administered

questionnaire, created for the PDP (Reinisch et al., 1993),

includes 120 items from the original Eysenck Inventory of

Attitudes towardSex (Eysenck, 1976). Participants indicated

their agreement/disagreement on a three-point scale (yes, ?,

no; scored 2, 1, 0, respectively) with 179 statements about

various aspects of sexuality. There are two factors relevant to

sexual orientation: attraction tomales and attraction to females.

Each factor has six items and shows good internal consistency

(Cronbach’s alphas .88 for attraction tomales and .90 for attrac-

tion to females). Items for attraction to males and attraction to

femaleswereworded identically except for the sex of the object

of attraction. Questions (in Danish) were scattered throughout

the SAQ. The 12 questions about attraction to males/females

translated into English are as follows:

• IusuallytakealonglookwhenImeetanattractiveman/woman in the street.

• Male/female sexual organs are attractive. • I often have fantasies about male/female sex partners. • Now and then I think about sex when I am in an attractive man’s/woman’s company.

• I sometimes have fantasies about being with two or more men/women at the same time.

• I regularly meet men/women whom I find attractive.

Table 2 Descriptive statistics for progesterone exposure variables (n= 34)

Progesterone exposure variables N (%)

Timing of exposure (trimesters)

1st only 14 41.2

1st–2nd 12 35.3

2nd only 6 17.6

2nd–3rd 2 5.9

3rd only 0 0.0

Total dosage (mg)

40–300 11 32.4

301–999 14 41.2

1000–1999 5 14.7

2000–5400 4 11.8

Duration of exposure (days)

8–29 9 26.5

30–60 12 35.3

61–120 8 23.5

121–158 5 14.7

Average daily dosage (mg/day)

3–9 16 47.1

10–25 7 20.6

26–50 11 32.4

Arch Sex Behav (2017) 46:1239–1249 1243

123

Procedure

Thestudywasapprovedbytheappropriatereviewboardsforthe

protectionofhumansubjects inboth theU.S.andDenmark.The

data presented in this article assessing sexual orientation rep-

resent a subset of a large evaluation battery (Reinisch et al.,

1993).Thepurposeandproceduresfor thestudywereexplained

to participants, and informed consent was obtained. A psychol-

ogist supervised the collection of questionnaire data and con-

ducted the interview during a full day of evaluation at the Insti-

tute for PreventiveMedicine. Evaluators and participants were

blind regarding treatment status.

Data Analysis

We hypothesized that same-sex behavior and attraction would

be higher for the exposed compared to the unexposed partici-

pants. Data were first examined for interactions between sex of

participant and exposure to lutocyclin. Finding none, data from

men and women were then combined for statistical analysis of

exposure effects, with the exception of scores for attraction to

males and attraction to females as these are more easily under-

stoodwhen presented separately by sex. For dichotomous vari-

ables, Tango’s (1998) test of the differences in proportions in

matchedpairswas used.Unlike theMcNemar test, Tango’s test

accommodates292 tableswithoff-diagonal zerocells. For con-

tinuous variables, paired t tests were performed to compare data

from exposed and unexposed participants. Spearman’s rho was

used to evaluate the correlation between attraction to males and

attraction to females. Relationships between progesterone treat-

ment parameters and outcomes of interest were assessed by the

Kolmogorov–SmirnovZ testofequalityofdistributions.We

report p values for two-tailed tests, a conservative criterion

given our directional hypotheses which would justify use of

one-tailed tests.

Results

As shown in Table 3, compared to their matched controls,

exposedcasesshowedaconsistentpatternofhigherpercentages

of:

1. Self-labeled identification as other than heterosexual (i.e.,

homosexual, bisexual, or‘‘don’t know’’) (20.6% exposed,

0% controls, p\.01). Among the exposed men, one iden- tified as homosexual, two as bisexual, and two said‘‘don’t

know.’’Among exposed women, two identified as bisex-

ual. All other subjects, exposed and unexposed, self-iden-

tified as heterosexual;

2. ‘‘Ever Attracted to Own Sex’’ (29.4% exposed, 5.9%

controls, p= .02);

3. ‘‘Currently Attracted to Own or Both Sexes’’ (17.6% ex-

posed, 2.9% controls, p\.06); and 4. Various sexual behaviors with their own sex including

‘‘kissed own sex’’; partially and fully undressed in a sexual

situation; ‘‘intercourse’’; ‘‘gone to bed’’; and ‘‘masturbated

together’’ (range 14.7–24.2% exposed cases, 0–9.1% of

controls). In general, behavioral patternswere consistent for

individuals. For example, all those reporting ‘‘intercourse’’

with a person of the same sex also reported ‘‘going to bed’’

with; being fully and partly undressed in a sexual situation

with; and kissing someone of the same sex.

None of those who identified as other than heterosexual had

own sex attractions or engaged in these same-sex behaviors

were concordant with their matches.

Exposure status was not associated with heterosexual expe-

rience—all participants reported sexual behaviorwith the other

sex.Thesmallnumberofcaseswhoengagedinsame-sexsexual

behaviorsprecludedstatisticalanalysesof‘‘AgeatFirstEngage-

ment’’ in those behaviors, but this measure for heterosexual

behaviorsdidnotdifferaccordingtoexposurestatus(seeTable4).

For men, scores on the attraction to males scale were signif-

icantly higher for exposed cases compared to controls, paired

t(16)=2.76,p\.02, two-tailed, but scores did not differ for the attraction to females scale (see Table5). For women, scores on

attraction to females scale were not different between exposed

and unexposed cases, but there was a statistical trend toward

higher scores on the attraction to males scale for exposed

women,paired t(16)=1.92,p= .07, two-tailed.Thus,exposure

was positively associatedwith higher scores on the attraction to

males scale regardless of sex, total group ofmales, and females

combined paired t(33)=3.31, p\.01, two-tailed. Although a bipolarmodelof sexualorientation(Kinseyetal.,1948;Sanders

et al., 1990)would predict a strongnegative relationshipbetween

scale scores for attraction to males and attraction to females, this

was not the case (for men, Spearman’s rho=-.10; for women,

rho= .23; both ns).

In light of findings linking birth order and number of older

brothers to homosexual orientation among men (Blanchard &

Bogaert, 1996; Cantor, Blanchard, Paterson,&Bogaert, 2002),

this possible confound was examined. Neither birth order nor a

number of older brothers confound the current findings. Not

surprisinggiven thematching,birthorderdidnotdifferbetween

exposed and unexposed men (M=1.76, SD= .96) and the

numberwhohadolderbrotherswasthesamefortheexposedand

unexposed groups (n=5 for each group).

A systematic investigation of the relationship between pro-

gesterone treatment parameters (i.e., total dosage, averagedaily

dosage, timing,anddurationofprogesteroneexposure)andout-

comesof interestwasprecludedby thehighvariability inmater-

nal medical treatment and the intercorrelations among the var-

ious treatmentparameters.Nonetheless, it isnoteworthy that the

seven individualswho self-identified as other thanheterosexual

1244 Arch Sex Behav (2017) 46:1239–1249

123

wereexposed tohigher totaldosages (median=1000mg, range

450–5400mg)overlongerdurations(median=105days,range

20–120days) than thosewhoidentifiedasheterosexual (median

total dosage=500mg, range 40–2700mg, K–S Z=-2.28,

p= .02; median duration=47days, range 8–158days, K–S

Z=-2.24, p\.03).

Discussion

In summary,we observed consistent findings across samples of

menandwomenprenatally exposed to exogenousprogesterone

for a set of variables directly reflective of sexual orientation.

Relative to unexposed controls, prenatal exposure to proges-

terone was significantly associated with: (1) decreased likeli-

hood of self-identification as heterosexual; (2) increased like-

lihood of having engaged in same-sex sexual behaviors; (3)

increased likelihood of reporting attraction to the same or both

sexes,and(4)higherscoresontheattractiontomalesscale.Pro-

gesterone exposurewas not associatedwith a decrease inmea-

sured heterosexual behavior.Amongprogesterone-exposed cases,

non-heterosexual identity was shown to be associated with higher

total dosages and longer duration of prenatal exposure to proges-

terone.

We recognize thatmany factorsmay affect the development

of sexual orientation and that the prenatal hormone environ-

ment is only one of these. In considering the epigenetic mech-

anism(s) bywhich prenatal exposure to exogenous progesterone

may influence sexual orientation, it is relevant that progesterone

appears to have both antiandrogenic and antiestrogenic potential

duringearlycriticalorsensitiveperiodsofdevelopment(Connolly,

Handa,&Resko,1988;Dorfman,1967;Kesteretal.,1980;Sanders

Table 3 Comparison of sexual orientation, attraction, and behavior variables for prenatally progesterone-exposed (Exp) and unexposed (Un) participants

Men

(17 pairs)

Women

(17 pairs)

Total group

(34 pairs)

z Statistica p (two-tailed)b

Exp Un Exp Un Exp Un

n n n n n (%) n (%)

Same sex

Non-heterosexual self-labeled identityc,d,e 5 0 2 0 7 20.6 0 0 2.56 .008

Ever attracted to own sexc 6 0 4 2 10 29.4 2 5.9 2.31 .021

Current attraction to own or both sexesc,e 3 0 3 1 6 17.6 1 2.9 1.88 .059b

Kissed own sexc,e 3 0 4 1 7 20.6 1 2.9 2.12 .034

Has been partially undressed in a sexual situation with own sexc,e,f 3 0 4 1 7 20.6 1 2.9 2.12 .034

Has been fully undressed in a sexual situation with own sexc,e,f 2 0 4 1 6 17.6 1 2.9 1.88 .059b

‘‘Intercourse’’with own sexc,e,f 2 0 3 0 5 14.7 0 0 2.23 .025

‘‘Gone to bed’’with person of own sexe,f,g 2 0 4 1 6 17.6 1 2.9 1.89 .059b

Masturbated in the presence of same sexg 6 2 2 1 8 24.2 3 9.1 1.67 .095b

Other (‘‘opposite’’) sex

Kissed other sexc 17 17 17 17 34 100 34 100 na na

Has been partially undressed in a sexual situation with other sexc 17 17 17 17 34 100 34 100 na na

Has been fully undressed in a sexual situation with other sexc 17 17 17 17 34 100 34 100 na na

Intercourse with other sexc,h 16 17 17 17 33 97.1 34 100 1.00 ns

Masturbated in the presence of other sexg 6 8 4 6 10 30.3 14 42.4 1.15 ns

a Tango’s (1998) test of the differences in proportions in the pair-sample design was used (na = Not applicable) b We have used a conservative criterion for statistical significance. The hypotheses are directional, and therefore, one-tailed tests may be justified. If

one-tailed tests are used, all same-sex variables in this table would be significant at p\.05 (na = Not applicable) c From the interview d Self-identification as lesbian, homosexual, bisexual, or‘‘don’t know’’was recoded as non-heterosexual. Specifically, among the exposed men one

identified as homosexual, two as bisexual, and two said‘‘don’t know.’’Among exposedwomen, two identified as bisexual. All other subjects, exposed

and unexposed, self-identified as heterosexual e Noneof thosewho identifiedasother thanheterosexual; hadownsexattractions; or engaged in these same-sexbehaviors,were concordantwith their

matches f In general, behavioral patterns were consistent for individuals. For example, all those reporting ‘‘intercourse’’with a person of the same sex, also

reported‘‘going to bed’’with, being fully and partly undressed in a sexual situation with, and kissing someone of the same sex g From the Sexual Behavior Inventory h Only one participant, a lutocyclin-exposed man (who reported same-sex‘‘intercourse’’), did not report having had heterosexual intercourse

Arch Sex Behav (2017) 46:1239–1249 1245

123

& Reinisch, 1985). Exogenous progesterone has been demon-

strated to have physiological effects during gestation despite the

presenceofhighendogenous levels (Aboulghar, 2009; daFonseca

et al., 2009; Palagiano et al., 2004; Silver et al., 1999). Exogenous

progesterone administrated in associationwith invitro fertilization

hasbeen suggested as a factor in increased rates of hypospadias in

malenewborns (Carmichael et al., 2005;Dorfman,1967;Silver

et al., 1999). Additionally, emerging researchwith rodents sug-

gests progesterone andprogesterone receptorsmayplay an impor-

tant role in thedevelopmentofdimorphic sexual, cognitive, social,

and affective behavior differentiation (Wagner, 2008; Wagner,

Nakayama, & De Vries, 1998). While the direct physiological

mediators of the effects of prenatal progesterone exposure await

identification,ourfindingsmaybeconsideredabehavioralbioas-

say of such underlying effects (Reinisch, 1974; Reinisch et al.,

1991). This bioassay makes it clear that exposure to exogenous

progesterone during a sensitive period of humanCNS differenti-

ationmaypermanentlyaffectneuralfunctionandultimatelyinflu-

ence later behavior. It is also possible thatmedical treatmentwith

progesterone isamarkerofmaternalprogesteronedeficiencyand

thatvariation inendogenousmaternalprogesterone levelsmaybe

animportantfactorinnaturallyoccurringdifferencesinsexualori-

entation. The detection of a relationship between prenatal expo-

sure to exogenous progesterone and sexual orientation in early

adulthood,despitemanyinterveningfactors,supports thehypoth-

esis that the prenatal hormone environment is influential.

Howmight the addition of exogenousprogesterone into an

already rich mixture of gestational steroids, including endoge-

nous progesterone, affect the nervous system and subsequent

behavioral development of the offspring? First, in keepingwith

themostcurrentclinicalresearch,thishormonalmedicationwas,

and continues to be, administered by physicians to treat symp-

tomsof staining,bleeding, topreventprematurity in twins (Rouse

etal.,2007;Schuitetal.,2015),andtopreventpretermbirth(Dodd

et al., 2013; Merlob, Stahl, & Klinger, 2012) and for imminent

spontaneousabortion(daFonsecaetal.,2009).Thisdemonstrates

its capacity to have some meaningful physiological impact. It is

currentlyusedforpain,uterinecontractions,andinadequateluteal

phase, and its effectiveness has been demonstrated on both ultra-

sound assessment of uterine contraction and a pain scale (Pala-

gianoetal.,2004).Second,progesteronewasadministeredexoge-

nously at pharmacological levels during periods of gestation

known to be sensitive to the influence of steroid hormones on

sexualdevelopment(seeTable2).Third,exogenouslyintroduced

hormonesmaydiffer from (and thus have different potency than)

their endogenous counterparts in how they aremetabolized, their

receptor affinity and sensitivity, and their systemic versus local-

ized action. Thus, it is possible that, compared to endogenous

levels, even relatively limited physiological dosesmay have sig-

nificant effects on various systems when administered exoge-

nously.

Table 4 Comparison of ages of first engagement in sexual behaviors with other sex for prenatally progesterone-exposed and unexposed participants (34 pairs)

Other-sex variable Exposed Unexposed Paired t p

M (SD) M (SD)

Age at first kissing other sex (years) 13.81 (2.77) 13.10 (.40) 1.21 ns

Age at first being partially undressed in a sexual situation with other sex (years) 14.82 (2.43) 14.10 (2.60) 1.33 ns

Age at first being fully undressed in a sexual situation with other sex (years) 15.72 (2.50) 14.97 (2.43) 1.35 ns

Age at first intercourse with other sex (years) 16.39 (2.29) 15.81 (2.75) 1.02 ns

Table 5 Comparison of scores for attraction to males and attraction to females for prenatally progesterone-exposed (Exp) and unexposed (Un) participants within sex

Score Males (17 pairs) Females (17 pairs)

Exp Un Paired t p (two-tailed) Exp Un Paired t p (two-tailed)

Attraction to males

M .52 .13 2.76 .014 1.57 1.40 1.92 .073

SD .56 .18 .29 .48

Attraction to females

M 1.76 1.81 \1 ns .75 .58 \1 ns SD .43 .23 .54 .51

Possible scores ranged from 0 to 2

1246 Arch Sex Behav (2017) 46:1239–1249

123

A limitation common to studies of sexuality is their reliance

on self-report. The non-normative status of same-sex attraction

andbehavior tends toproduce a social desirability effect toward

underreporting these behaviors. Any such bias would have

servedtominimizedifferencesbetweengroups.Similarly,small

sample size often results in limited statistical power. It is also

important to note that in research on human prenatal exposures,

our34caseswithasingleunconfoundedtypeofhormonalexpo-

sure represent an unusually large number. More detailed eval-

uationsoftreatmentparameterswerenotpossiblegiventhewide

range of individual treatment regimes and the colinearity of the

treatmentvariables.Despitethevariationintreatmentregimens,

theextensivecomparableprospectivedataavailableonbothindex

cases and controls provide confidence in the treatment status for

bothgroupsanda relatively largepoolofmatchingvariables.Our

groups were carefully matched on 14 highly relevant prenatal,

perinatal, and maternal factors which should serve to minimize

confounds incomparisonsbetweenexposedandcontrol subjects.

It shouldbe taken intoaccount thatparticipantswere in their early

to mid-20s when evaluated and that the lifetime range of their

patterns of sexual behavior and attractionswas not likely to have

been fully realized by early adulthood. Follow-up studies would

be required to evaluate the levels of same-sex behavior and/or

attraction thatmay have been revealed in subsequent decades. In

keeping with the strengths of the current design, we found con-

sistent statistically significant effects across a number of different

measures supporting our hypotheses.

What are the theoretical implications of our findings regard-

ing the conceptualizationof the nature of sexual orientation and

its biological bases?Support for the commonlyheldbipolarmodel

of sexual orientation (a unidimensional model where one pole

representshomosexualityand theother, heterosexualityormas-

culinity vs. femininity; Kinsey et al., 1948) requires a strong

negative correlation between scale scores on attraction tomales

and attraction to females (Sanders et al., 1990) as well as that

betweensameandopposite sexexperience.However, our study

fails to support thismodel since inbothmales and females these

correlationswerelowandnotsignificant.Therefore,wehypoth-

esize that sexual orientation may be more accurately and pro-

ductively conceptualized in terms of a two-dimensional model

in which the dimensions of heterosexuality and homosexuality

are relatively independent, with each dimension having a high

and low pole, perhaps reflecting different neurodevelopmental

pathways (Olvera-Hernandez, Chavira, & Fernandez-Guasti,

2015;Sandersetal.,1990;Storms,1988).Suchaperspectivefits

well with similar models we have described for the differentia-

tion of masculinity and femininity in the context of the devel-

opment of more general aspects of gender identity and role

(Reinisch & Sanders, 1987; Reinisch et al., 1991). Method-

ologically, our results emphasize that studies of sexual

expression,whichfocusonsame-sexor‘‘opposite’’-sexbehavior

to the exclusion of the other, may obscure the prevalence of

bisexual patterns.

In conclusion, these findings reveal that prenatal progester-

onehasbeenanunderappreciatedfactor inhumanpsychosexual

development (as are the actions of fetal testosterone or extern-

ally introduced endocrine disruptors). Our findings suggest

that natural perturbations in endogenous progesterone dur-

inggestationmayaffect individual differences in the expres-

sionofadultsexualorientation.Specifically,progesteroneexpo-

surewas found to be related to increased non-heterosexual self-

identification,attraction to thesameorbothsexes,andsame-sex

sexual behavior. The findings challenge the prevailing view of

homosexual interest andbehaviorasa simple reflectionof femi-

nization/demasculinization in males and masculinization/de-

feminizationinfemales.Incontrast,thecurrentresearchunderli-

nes thenecessityofconcurrentmeasurementofawidespectrum

of both same-sex and‘‘opposite’’-sex behaviors and attitudes in

any study of human sexual expression.

The current findings highlight the likelihood that prenatal

exposuretoprogesteronemayhavelong-termbehavioralseque-

lae related to sexuality in humans, even in the absence of mor-

phologicaleffectsonthegenitalia. Inlightof thecontinuedtreat-

ment of human pregnancies with progesterone (and other pro-

gestogens), further studies of offspring of progesterone-treated

pregnancies are warranted and may provide important insights

into the role of this hormone in human behavioral development

(Dodd et al., 2013).

Acknowledgements WethankLeonardA.Rosenblum for editingof the article, CarolynS.Kaufman for research assistanceduringdata collection

and archiving, and Brandon Hill for assistance with literature searches.

Funding This research was supported in part by US Public Health Ser- viceGrantsDA05056toJMRandSAS,GrantsHD17655andHD20263to

JMR, Grant 9700093 from the Danish Research Councils to ELM. Some

preliminary analyses of a portion of the complete data presented in final

form in this paper were previously described in a thesis by Caroline Ripa,

University of Copenhagen, 2002.

Compliance with Ethical Standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical Approval Existing data from human research participants were used. All procedures performed in studies involving human participants

were in accordance with the ethical standards of the institutional and/or

national researchcommitteeandwith the1964HelsinkiDeclarationand its

later amendments or comparable ethical standards.

Informed Consent At the time of data collection, informed consent was obtained from all individual participants included in the study.

Arch Sex Behav (2017) 46:1239–1249 1247

123

References

Aboulghar,M.(2009).Luteal support in reproduction:When,whatandhow?

Current Opinion in Obstetrics and Gynecology, 21, 279–284.

Adkins-Regan, E. (1988). Sex hormones and sexual orientation in animals.

Psychobiology, 16, 335–347.

Baker,V.L., Jones,C.A.,Doody,K., Foulk,R.,Yee,B.,Adamson,G.D.,… Soules, M. (2014). A randomized, controlled trial comparing the effi-

cacyandsafetyofaqueoussubcutaneousprogesteronewithvaginalpro-

gesterone for luteal phase support of in vitro fertilization. Human

Reproduction, 29, 2212–2220.

Balthazart, J. (2011).Minireview: Hormones and human sexual orientation.

Endocrinology, 152, 2937–2947.

Blanchard,R.,&Bogaert,A.F.(1996).Homosexualityinmenandnumberof

older brothers. American Journal of Psychiatry, 153, 27–31.

Cantor, J.M., Blanchard, R., Paterson, A. D., &Bogaert, A. F. (2002). How

many gay men owe their sexual orientation to fraternal birth order?

Archives of Sexual Behavior, 31, 63–71.

Carmichael,S.L.,Shaw,G.M.,Laurent,C.,Croughan,M.S.,Olney,R.S.,&

Lammer, E. J. (2005). Maternal progestin intake and risk of hypospa-

dias. Archives of Pediatric and Adolescent Medicine, 159, 957–962.

Cohen-Bendahan,C., van deBeek, C.,&Berenbaum, S.A. (2005). Prenatal

sex hormone effects on child and adult sex-typed behavior: Methods

and findings.Neuroscience and Biobehavioral Reviews, 29, 353–384.

Connolly,P.B.,Handa,R.J.,&Resko,J.A.(1988).Progesteronemodulation

of androgen receptors in thebrainandpituitaryofmaleguineapigs.En-

docrinology, 122, 2547–2553.

daFonseca,E.B.,Bittar,R.E.,Damião,R.,&Zugaib,M.(2009).Prematurity

prevention:Theroleofprogesterone.CurrentOpinioninObstetricsand

Gynecology, 21, 142–147.

Dodd, J. M., Jones, L., Flenady, V., Cincotta, R., & Crowther, C. A. (2013).

Prenatal administration of progesterone for preventing preterm birth in

women considered to be at risk of preterm birth. Cochrane Database

Systematic Review, 7,Article No. CD004947.

Dorfman,R. I. (1967). Invitrofertilizationisassociatedwithanincreasedrisk

of hypospadias. Anatomical Record, 57, 547–557.

Ehrhardt,A.A.,Grisanti,G.C.,&Meyer-Bahlburg,H.F.L. (1977).Prenatal

exposure to medroxyprogesterone acetate (MPA) in girls. Psychoneu-

roendocrinology, 2, 391–398.

Ellis, L., & Ames, M. A. (1987). Neurohormonal functioning and sexual

orientation:A theory of homosexuality-heterosexuality.Psychological

Bulletin, 101, 233–258.

Ellis,L.,&Hellberg, J. (2005).Fetal exposure toprescriptiondrugs andadult

sexual orientation. Personality and Individual Differences, 39, 225–

236.

Eysenck, H. J. (1976). Sex and personality. Austin, TX:University of Texas

Press.

Gooren,L. (2006).Thebiologyofhumanpsychosexual differentiation.Hor-

mones and Behavior, 50, 589–601.

Grimbos, T., Dawood, K., Burris, R., Zucker, K. J., & Puts, D. A. (2010).

Sexual orientation and the second to fourth finger length ratio: Ameta-

analysis in men and women. Behavioral Neuroscience, 124, 278–287.

Hartwig, I.R.,Bruenahl,C.A.,Ramesch,K.,Keil,T., Inman,M.,Arck,P.C.,

& Pincus, M. (2014). Reduced levels of maternal progesterone during

pregnancy increase the risk for allergic airwaydiseases in femalesonly.

Journal of Molecular Medicine, 92, 1093–1104.

Hines,M.(2004).Psychosexualdevelopmentinindividualswhohavefemale

pseudohermaphroditism. Child and Adolescent Psychiatric Clinics of

North America, 13, 641–656.

Hines, M. (2010). Sex-related variation in human behavior and the brain.

Trends in Cognitive Science, 14, 448–456.

Hines,M. (2011). Prenatal endocrine influences on sexual orientation andon

sexually differentiated childhood behavior. Frontiers in Neuroen-

docrinology, 32, 170–182. doi:10.1016/j.yfrne.2011.02.006.

Hines, M., Constantinescu, M., & Spencer, D. (2015). Early androgen

exposure and human gender development. Biology of Sex Differ-

ences, 6. doi:10.1186/s13293-015-0022-1.

Hiraichi, K., Sasaki, S., Shikishima, C., & Ando, J. (2012). The second to

fourth digit ratio (2D:4D) in a Japanese twin sample: Heritability, pre-

natal hormone transfer, and associationwith sexual orientation.Archives

of Sexual Behavior, 41, 711–724.

Jordan-Young, R. M. (2012). Hormones, context, and ‘‘brain gender’’: A

reviewofevidence fromcongenital adrenalhyperplasia.SocialScience

andMedicine, 74, 1738–1744.

Junager, S. A.,& Schleisner, A. H. (1963). Lægeforeningensmedicinforteg-

nelse [Danish Physician’s Desk Reference]. Copenhagen: Læge-

foreningens Forlag.

Kester, P., Green, R., Finch, S. J., & Williams, K. (1980). Prenatal ‘female

hormone’ administration and psychosexual development in human

males. Psychoneuroendocrinology, 5, 269–285.

Kinsey,A.C.,Pomeroy,W.B.,&Martin,C.E.(1948).Sexualbehaviorinthe

human male. Philadelphia, PA:W. B. Saunders.

Kinsey,A.C.,Pomeroy,W.B.,Martin,C.E.,&Gebhard,P.H. (1953).Sexual

behavior in the human female. Philadelphia, PA:W. B. Saunders.

Merlob,P.,Stahl,B.,&Klinger,G. (2012).17a-hydroxyprogesteronecaproate

for prevention of recurrent spontaneous preterm birth. Reproductive

Toxicology, 33, 15–19.

Meyer-Bahlburg, H. F. L. (1984). Psychoendocrine research on sexual orien-

tation:Current status and futureoptions.Progress inBrainResearch, 61,

375–398.

Meyer-Bahlburg, H. F. L., Ehrhardt, A. A., Rosen, L. R., Gruen, R. S.,

Verdiano, N. P., Vann, F. H., & Neuwalder, H. F. (1995). Prenatal

estrogens and the development of homosexual orientation. Develop-

mental Psychology, 31, 12–21.

Northen, A. T., Norman, G. S., Anderson, K., Moseley, L., Divito, M.,

Cotroneo, M., … Anderson, G. D. (2007). Follow-up of children exposed in utero to 17a-hydroxyprogesterone caproate comparedwith placebo.Obstetrics and Gynecology, 110, 865–872.

Olvera-Hernandez, S., Chavira,R.,&Fernandez-Guasti,A. (2015). Prenatal

letrozole produces a subpopulation of male rats with same sex-prefer-

ence and arousal as well as female sexual behavior. Physiology and

Behavior, 139, 403–411.

Palagiano,A.,Bulletti,C.,Pace,M.C.,DeZiegler,D.,Cicinelli,E.,&Izzo,A.

(2004).Effectsofvaginalprogesteroneonpainanduterinecontractility

in patientswith threatened abortion before twelveweeks of pregnancy.

Annals New York Academy of Sciences, 1034, 200–210.

Reinisch, J.M. (1974).Fetalhormones, thebrain, andhumansexdifferences:

Aheuristic, integrativereviewoftherecentliterature.ArchivesofSexual

Behavior, 3, 51–90.

Reinisch, J. M. (1977). Prenatal exposure of human foetuses to synthetic

progestin and oestrogen affects personality.Nature, 266, 561–562.

Reinisch, J. M. (1981). Prenatal exposure to synthetic progestins increases

potential for aggression in humans. Science, 211, 1171–1173.

Reinisch, J. M., & Karow, W. G. (1977). Prenatal exposure to synthetic

progestins and estrogens: Effects on human development. Archives of

Sexual Behavior, 6, 257–288.

Reinisch, J. M., Mortensen, E. L., & Sanders, S. A. (1993). The Prenatal

Development Project. Acta Psychiatrica Scandinavica Supplement,

370, 54–61.

Reinisch,J.M.,&Sanders,S.A.(1984).Prenatalgonadalsteroidal influences

on gender-related behavior.Progress in Brain Research, 61, 407–416.

Reinisch, J. M., & Sanders, S. A. (1987). Behavioral influences of prenatal

hormones. InC.B.Nemeroff&P.T. Loosen (Eds.),Handbook of clin-

ical psychoneuroendocrinology (pp. 431–448). New York, NY: Guil-

ford Press.

Reinisch, J. M., Sanders, S. A., Mortensen, E. L., & Rubin, D. B. (1995). In

uteroexposure tophenobarbital and intelligencedeficits inadulthuman

males. Journal of theAmericanMedical Association, 274, 1518–1524.

1248 Arch Sex Behav (2017) 46:1239–1249

123

Reinisch, J. M., Ziemba-Davis, M., & Sanders, S. A. (1991). Hormonal

contributionstosexuallydimorphicbehavioraldevelopmentinhumans.

Psychoneuroendocrinology, 16, 213–278.

Rosenbaum,P.R.,&Rubin,D.B.(1985a).Thebiasduetoincompletematch-

ing. Biometrics, 41, 103–116.

Rosenbaum, P. R., & Rubin, D. B. (1985b). Constructing a control group

using multivariate matched sampling methods that incorporate the

propensity score. The American Statistican, 39, 33–38.

Rouse, D. J., Caritis, S. N., Peaceman, A. M., Sciscione, A., Thom, E. A.,

Spong, C. Y.,… Anderson, G. (2007). A trial of 17a-hydroxyproges- teroneCaproate topreventprematurity inTwins.NewEnglandJournal

of Medicine, 357, 454–461.

Sanders, S. A., & Reinisch, J. M. (1985). Behavioral effects on humans

of progesterone-related compounds during development and in the

adult. In D. Ganten & D. Pfaff (Eds.), Current topics neuroen-

docrinology (Vol. 5): Actions of progesterone on the brain (pp.

175–205). Heidelberg: Springer.

Sanders, S. A., Reinisch, J.M.,&McWhirter, D. P. (1990). Homosexuality/

heterosexuality: An overview. In D. P.McWhirter, S. A. Sanders, & J.

M.Reinisch(Eds.),Homosexuality/heterosexuality:Conceptsofsexual

orientation (pp. 10–12). NewYork, NY: Oxford University Press.

Schuit, E., Stock, S., Rode, L.,Rouse,D. J., Lim,A.C.,Norman, J. E.,… Mol, B. W. (2015). Effectiveness of progestogens to improve

perinatal outcome in twin pregnancies: An individual participant

data meta-analysis. British Journal of Gynecology, 122, 27–37.

Silver, R. I., Rodriguez, R., Chang, T. S., & Gearhart, J. P. (1999). In vitro

fertilization is associatedwithan increased riskofhypospadias.Journal

of Urology, 161, 1954–1957.

Storms,M.D. (1988). Theories of sexual orientation. Journal of Personality

and Social Psychology, 38, 783–792.

Tango, T. (1998). Equivalence test and confidence interval for the difference

in proportions for the paired-sample design. Statistics in Medicine, 17,

891–908.

Valla,J.,&Ceci,S.J. (2011).Cansexdifferencesinsciencebetiedtothelong

reach of prenatal hormones? Brain organization theory, digit ratio

(2D:4D), and sex difference in preferences and cognition.Perspectives

in Psychological Science, 6, 134–136.

Villumsen, A. L. (1970). Environmental factors in congenital malforma-

tions:Aprospective studyof9006humanpregnancies.Copenhagen:

F.A.D.L.S. Forlag.

Wagner, C. K. (2008). Minireview: Progesterone receptors and neural

development: A gap between bench and bedside? Endocrinology,

149, 2743–2749.

Wagner, C. K., Nakayama, A. Y., & De Vries, G. J. (1998). Potential role of

maternalprogesteroneinthesexualdifferentiationofthebrain.Endocrinol-

ogy, 139, 3658–3661.

Wong,W.I.,&Hines,M. (2015). Interpretingdigit ratio (2D:4D)—behavior

correlations: 2D:4D sex difference, stability, and behavioral correlates

and their replicability in young children.Hormones and Behavior, 78,

86–94.

Arch Sex Behav (2017) 46:1239–1249 1249

123

Archives of Sexual Behavior is a copyright of Springer, 2017. All Rights Reserved.

  • Prenatal Exposure to Progesterone Affects Sexual Orientation in Humans
    • Abstract
    • Introduction
    • Method
      • Participants
      • Measures
        • Interview Data
        • Same-Sex Variables
        • Other-Sex Variables
        • Questionnaire Data
          • Sexual Behavior Inventory (SBI)
          • Sexual Attitudes Questionnaire (SAQ)
      • Procedure
      • Data Analysis
    • Results
    • Discussion
    • Acknowledgements
    • References

Get help from top-rated tutors in any subject.

Efficiently complete your homework and academic assignments by getting help from the experts at homeworkarchive.com